ASX Announcement | 17 November 2026 AdAlta Limited (ASX:1AD) US FDA Orphan Drug Designation for EW-001 in mesothelioma assigned to AdAlta AdAlta now holds a valuable US regulatory asset for its lead CAR-T therapy, following its first pre-IND meeting with the FDA Investment highlights • The US...
EW-001 Orphan Drug Designation, pre-IND update
Filed with ASX · · 4 pages · English
Summary by 6ix AI
This designation provides AdAlta with significant regulatory advantages, including market exclusivity and financial incentives for development. The pre-IND meeting confirmed the potential to utilize existing preclinical and clinical data for the IND submission, supporting the company's clinical trial preparations in Australia.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Earlier from AdAlta
- $1.4m additional RDTI refund
- Letter to Shareholders, Notice of AGM & Proxy Form
- Change of AGM Date
- Quarterly Appendix 4C and Activities Report
- RDTI receipt, Advanced Overseas Finding
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta